Evidence map›Paper›PMID 38236205›Full record

ArticleeLife2024

An optogenetic cell therapy to restore control of target muscles in an aggressive mouse model of amyotrophic lateral sclerosis.

J Barney Bryson, Alexandra Kourgiantaki, Dai Jiang, Andreas Demosthenous, Linda Greensmith

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J Barney BrysonDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-5486-0258
Alexandra KourgiantakiDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Dai JiangDepartment of Electronic and Electrical Engineering, University College London, London, United Kingdom.
Andreas DemosthenousDepartment of Electronic and Electrical Engineering, University College London, London, United Kingdom.
Linda GreensmithDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-7839-5052
Queen Mary University of London · GB

Funding

Medical Research Council MR/R011648/1Motor Neurone Disease Association Bryson 965-799
6 · The paper itself

Abstract

Breakdown of neuromuscular junctions (NMJs) is an early pathological hallmark of amyotrophic lateral sclerosis (ALS) that blocks neuromuscular transmission, leading to muscle weakness, paralysis and, ultimately, premature death. Currently, no therapies exist that can prevent progressive motor neuron degeneration, muscle denervation, or paralysis in ALS. Here, we report important advances in the development of an optogenetic, neural replacement strategy that can effectively restore innervation of severely affected skeletal muscles in the aggressive SOD1

Indexed as

Amyotrophic Lateral SclerosisAnimalsCell- and Tissue-Based TherapyDisease Models, AnimalHumansMiceMuscle, SkeletalOptogeneticsParalysisALSAmyotrophic Lateral Sclerosiscell transplantmotor neuronsmouseoptogeneticsparalysisregenerative medicinestem cells

Identifiers

PMID38236205
PMCPMC10945574
OpenAlexW4386069572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.